Kalaris Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -10 | -10 | ||
EBITDA | -11,833 | -10,791 | -11,894 | -11,350 |
EBIT | -10,801 | -12,256 | ||
Net Income | -10,856 | -9,998 | -11,894 | -11,350 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -13,350 | -9,334 | -11,516 | -14,885 |
Cash | 34,427 | 98,054 | 42,387 | 88,426 |
Basic Shares | 23,723 | 22,902 | 18,701 | 18,701 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -13 | |||
EBITDA | -46,139 | -58,769 | -14,012 | -15,250 |
EBIT | -46,152 | -13,464 | -14,006 | |
Net Income | -43,438 | -58,769 | -14,699 | -15,485 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -43,176 | -67,705 | -14,132 | -9,779 |
Cash | 98,054 | 118,289 | 3,169 | 3,059 |
Basic Shares | 15,267 | 5,008 | 4,524 | 3,332 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.46 |
2025-12-31 | -$0.44 |
2025-09-30 | -$0.64 |
2025-06-30 | -$0.61 |